Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SKAN Group AGFRA:7VG +2.54%66 EV-to-EBITDA is 38.40 as of Jul. 28, 2026, which is 17% above its 10-year median of 32.82. GuruFocus rates FRA:7VG with a GF Score™ of 66/100 and a GF Value™ of €91.67 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 510 Medical Devices & Instruments companies, SKAN Group AG ranks worse than 85.1% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SKAN Group AG's enterprise value is €1,461.1 Mil.
SKAN Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €38.1 Mil. Therefore, SKAN Group AG's EV-to-EBITDA for today is 38.40.
The historical rank and industry rank for SKAN Group AG's EV-to-EBITDA or its related term are showing as below:
FRA:7VG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.52 Med: 32.82 Max: 50.2
Current: 38.23
During the past 6 years, the highest EV-to-EBITDA of SKAN Group AG was 50.20. The lowest was 16.52. And the median was 32.82.
FRA:7VG's EV-to-EBITDA is ranked worse than 85.1% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.17
vs FRA:7VG: 38.23
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
SKAN Group AG (FRA:7VG) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SKAN Group AG's PE Ratio (TTM) for today is calculated as:
SKAN Group AG's share price for today is €60.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SKAN Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.774.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for SKAN Group AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7VG vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, SKAN Group AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SKAN Group AG EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SKAN Group AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SKAN Group AG's EV-to-EBITDA falls into.
SKAN Group AG's current Enterprise Value is €1,461.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SKAN Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €38.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SKAN Group AG (FRA:7VG) has a EV-to-EBITDA of 38.40 as of Jul. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SKAN Group AG. This is 17% above median its historical median of 32.82. Over the past decade, SKAN Group AG's EV-to-EBITDA has ranged from 16.52 to 50.20. According to the industry distribution chart, SKAN Group AG ranks #434 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 85.1%.
Is SKAN Group AG's EV-to-EBITDA too high?
SKAN Group AG's current EV-to-EBITDA of 38.40 is 17% above median its 10-year median of 32.82. Over the past 10 years, this metric has ranged from a low of 16.52 to a high of 50.20. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.17. SKAN Group AG's value of 38.40 is 171% above this industry median. Based on the distribution chart, SKAN Group AG ranks #434 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, SKAN Group AG has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SKAN Group AG's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, SKAN Group AG ranks #434 out of 510 companies for EV-to-EBITDA. This places SKAN Group AG in the lower half of its industry. The industry median EV-to-EBITDA is 14.17. SKAN Group AG's value of 38.40 is 171% above this benchmark. Historically, SKAN Group AG's own EV-to-EBITDA has ranged from 16.52 to 50.20 over the past decade. While the company's 10-year median is 32.82 vs. the industry median of 14.17, SKAN Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.17, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SKAN Group AG's current EV-to-EBITDA of 38.40 is 171% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SKAN Group AG. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SKAN Group AG's current EV-to-EBITDA is 38.40, which is 17% above median its own 10-year median of 32.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SKAN Group AG stock overvalued right now?
Based on GuruFocus' analysis, SKAN Group AG (FRA:7VG) is currently considered Significantly Undervalued. The stock's GF Value™ is €91.67, compared to a current price of €60.50 — trading 34% below its estimated fair value. The current EV-to-EBITDA is 38.40, which is 17% above median its 10-year median of 32.82 and 171% above the Medical Devices & Instruments industry median of 14.17. SKAN Group AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SKAN Group AG (FRA:7VG), the current EV-to-EBITDA is 38.40 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SKAN Group AG (FRA:7VG) Overvalued in 2026?
Based on GuruFocus' analysis, SKAN Group AG stock appears to be undervalued.
The current stock price of €60.50 is trading 34% below its estimated GF Value™ of €91.67.
GuruFocus considers SKAN Group AG to be Significantly Undervalued.
Key valuation signals for FRA:7VG:
EV-to-EBITDA: 38.40 (17% above median its 10-year median of 32.82)
GF Value™: €91.67 vs. price of €60.50 (34% below fair value)
Industry Position: 171% above the Medical Devices & Instruments median (#434 of 510)
No single metric tells the full story. See the FRA:7VG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SKAN Group AG is a market and technological company for isolators, cleanroom devices, and decontamination processes for the aseptic production of biopharmaceutical substances. The company offers its customers process support, services, and consumables. Its products include biological indicators, isolators, Laboratory/cleanroom equipment, laminar flow, safety workbenches, transfer systems, and others. The Firm has three operating segments: Equipment & solutions, Services & Consumables, and Other. The company generates the majority of its revenue from the Equipment & solutions segment. Geographically, the company derives revenue from Asia, Europe, Americas, and Other regions.
66GF Score
Get the complete analysis for FRA:7VG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7VG has been successfully added to your 
